# Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

> **NCT00950755** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 41 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)

## Key facts

- **NCT ID:** NCT00950755
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950755, "Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00950755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*